These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 30362181)

  • 61. A 1-year, prospective, observational study of Japanese outpatients with type 1 and type 2 diabetes switching from insulin glargine or detemir to insulin degludec in basal-bolus insulin therapy (Kumamoto Insulin Degludec Observational study).
    Shimoda S; Sato M; Sekigami T; Motoshima H; Yoshimura R; Fukuda K; Matsuo Y; Noda H; Okubo M; Ichimori S; Fujisawa K; Fukunaga M; Araki E;
    J Diabetes Investig; 2016 Sep; 7(5):703-10. PubMed ID: 27181264
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Glycaemic control and hypoglycaemia in people with type 2 diabetes switching from twice-daily basal insulin to once-daily insulin glargine 300 U/mL or insulin glargine 100 U/mL (EDITION 1 and EDITION 2 subgroup analysis).
    Roussel R; d'Emden MC; Fisher M; Ampudia-Blasco FJ; Stella P; Bizet F; Cali AMG; Wysham CH
    Diabetes Obes Metab; 2018 Feb; 20(2):448-452. PubMed ID: 28736942
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extension.
    Yki-Järvinen H; Bergenstal RM; Bolli GB; Ziemen M; Wardecki M; Muehlen-Bartmer I; Maroccia M; Riddle MC
    Diabetes Obes Metab; 2015 Dec; 17(12):1142-9. PubMed ID: 26172084
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Glycemic control with insulin glargine as part of an ethnically diverse, community-based diabetes management program.
    Philis-Tsimikas A; Zhang Q; Walker C
    Am J Ther; 2006; 13(6):466-72. PubMed ID: 17122525
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Achieve control: a pragmatic clinical trial of insulin glargine 300 U/mL versus other basal insulins in insulin-naïve patients with type 2 diabetes.
    Oster G; Sullivan SD; Dalal MR; Kazemi MR; Rojeski M; Wysham CH; Sung J; Johnstone B; Cali AM; Wei LJ; Traylor L; Anhalt H; Hull M; Van Vleet J; Meneghini LF
    Postgrad Med; 2016 Nov; 128(8):731-739. PubMed ID: 27690710
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Efficacy and safety of insulin glulisine in Japanese patients with type 1 diabetes mellitus.
    Kawamori R; Kadowaki T; Ishii H; Iwasaki M; Iwamoto Y
    Diabetes Obes Metab; 2009 Sep; 11(9):891-9. PubMed ID: 19614947
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Structured type 1 diabetes education delivered in routine care in Australia reduces diabetes-related emergencies and severe diabetes-related distress: The OzDAFNE program.
    Speight J; Holmes-Truscott E; Harvey DM; Hendrieckx C; Hagger VL; Harris SE; Knight BA; McIntyre HD
    Diabetes Res Clin Pract; 2016 Feb; 112():65-72. PubMed ID: 26688058
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Clinical research of insulin glargine U300 in type 1 diabetes mellitus patients with frequent hypoglycaemia: real-world experience.
    Kişioğlu SV; Demir AS; Tufekci D; Gunay YE; Coskun H; Ucuncu O; Nuhoglu I; Kocak M; Karakullukcu S; Ersoz HO
    Arch Med Sci Atheroscler Dis; 2021; 6():e102-e108. PubMed ID: 34027219
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Switching from premixed insulin to glargine-based insulin regimen improves glycaemic control in patients with type 1 or type 2 diabetes: a retrospective primary-care-based analysis.
    Sharplin P; Gordon J; Peters JR; Tetlow AP; Longman AJ; McEwan P
    Cardiovasc Diabetol; 2009 Feb; 8():9. PubMed ID: 19220880
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Initiation of insulin glargine in suboptimally controlled patients with type 2 diabetes: sub-analysis of the AT.LANTUS trial comparing treatment outcomes in subjects from primary and secondary care in the UK.
    Davies M; Evans R; Storms F; Gomis R; Khunti K
    Diabetes Obes Metab; 2007 Sep; 9(5):706-13. PubMed ID: 17697063
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus®) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study.
    Blevins TC; Dahl D; Rosenstock J; Ilag LL; Huster WJ; Zielonka JS; Pollom RK; Prince MJ
    Diabetes Obes Metab; 2015 Aug; 17(8):726-33. PubMed ID: 25974640
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Predictors of Glycemic Response and Change in HbA1c Following Newly Initiated Basal Insulin Among Insulin Naïve Adults With Type 2 Diabetes.
    Malek M; Aghili R; Ebrahim Valojerdi A; Khamseh ME
    Acta Med Iran; 2017 Sep; 55(9):556-562. PubMed ID: 29202547
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Persistent C-peptide is associated with reduced hypoglycaemia but not HbA
    Marren SM; Hammersley S; McDonald TJ; Shields BM; Knight BA; Hill A; Bolt R; Tree TI; Roep BO; Hattersley AT; Jones AG; Oram RA;
    Diabet Med; 2019 Sep; 36(9):1092-1099. PubMed ID: 30955221
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study.
    Seufert J; Pegelow K; Bramlage P
    Vasc Health Risk Manag; 2013; 9():711-7. PubMed ID: 24259985
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine in Patients With Type 2 Diabetes Previously Treated With Basal Insulin: IMAGINE 5.
    Buse JB; Rodbard HW; Trescoli Serrano C; Luo J; Ivanyi T; Bue-Valleskey J; Hartman ML; Carey MA; Chang AM;
    Diabetes Care; 2016 Jan; 39(1):92-100. PubMed ID: 26577417
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Effects of switching from NPH insulin to insulin glargine in patients with type 2 diabetes: the retrospective, observational LAUREL study in Italy.
    Bellia A; Babini AC; Marchetto PE; Arsenio L; Lauro D; Lauro R
    Acta Diabetol; 2014 Apr; 51(2):269-75. PubMed ID: 24275956
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A Randomized Trial of Insulin Glargine plus Oral Hypoglycemic Agents versus Continuous Subcutaneous Insulin Infusion to Treat Newly Diagnosed Type 2 Diabetes.
    Lin S; Chen M; Chen W; Lin K; Mu P; Zhu B; Xu W; Wang M; Weng J; Zeng L
    J Diabetes Res; 2018; 2018():2791584. PubMed ID: 30420969
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Comparative clinical outcomes of insulin degludec and insulin glargine 300 U/mL after switching from other basal insulins in real-world patients with type 1 and type 2 diabetes.
    Oya J; Nakagami T; Hasegawa Y; Katamine A; Kondo Y; Babazono T
    J Diabetes Investig; 2021 Nov; 12(11):1983-1991. PubMed ID: 33938149
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia.
    Johansen OE; Vanberg PJ; Kilhovd BK; Jørgensen AP
    Vasc Health Risk Manag; 2009; 5(1):121-8. PubMed ID: 19436668
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Continuous subcutaneous insulin infusion versus multiple daily injection regimens in children and young people at diagnosis of type 1 diabetes: pragmatic randomised controlled trial and economic evaluation.
    Blair JC; McKay A; Ridyard C; Thornborough K; Bedson E; Peak M; Didi M; Annan F; Gregory JW; Hughes DA; Gamble C;
    BMJ; 2019 Apr; 365():l1226. PubMed ID: 30944112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.